{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:46Z","timestamp":1786979986497,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Radiation segmentectomy using yttrium-90 plays an emerging role in the management of early-stage HCC. However, the value of early post-treatment MRI for response assessment is uncertain. We assessed the value of response criteria obtained early after radiation segmentectomy in predicting long-term response in patients with HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Patients with HCC who underwent contrast-enhanced MRI before, early, and 12\u00a0months after radiation segmentectomy were included in this retrospective single-center study. Three independent radiologists reviewed images at baseline and 1\n                      <jats:sup>st<\/jats:sup>\n                      follow-up after radiation segmentectomy and assessed lesion-based response according to mRECIST, LI-RADS treatment response algorithm (TRA), and image subtraction. The endpoint was response at 12\u00a0months based on consensus readout of two separate radiologists. Diagnostic accuracy for predicting complete response (CR) at 12\u00a0months based on the 1\n                      <jats:sup>st<\/jats:sup>\n                      post-treatment MRI was calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty patients (M\/F 60\/20, mean age 67.7\u00a0years) with 80 HCCs were assessed (median size baseline, 1.8\u00a0cm [IQR, 1.4\u20132.9\u00a0cm]). At 12\u00a0months, 74 patients were classified as CR (92.5%), 5 as partial response (6.3%), and 1 as progressive disease (1.2%). Diagnostic accuracy for predicting CR was fair to good for all readers with excellent positive predictive value (PPV): mRECIST (range between 3 readers, accuracy: 0.763\u20130.825, PPV: 0.966\u20131), LI-RADS TRA (accuracy: 0.700\u20130.825, PPV: 0.983\u20131), and subtraction (accuracy: 0.775\u20130.825, PPV: 0.967\u20131), with no difference in accuracy between criteria (\n                      <jats:italic>p<\/jats:italic>\n                      range 0.053 to\u2009&gt;\u20090.9).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>mRECIST, LI-RADS TRA, and subtraction obtained on early post-treatment MRI show similar performance for predicting long-term response in patients with HCC treated with radiation segmentectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance statement<\/jats:title>\n                    <jats:p>Response assessment extracted from early post-treatment MRI after radiation segmentectomy predicts complete response in patients with HCC with high PPV (\u2265\u20090.96).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>Early post-treatment response assessment on MRI predicts response in patients with HCC treated with radiation segmentectomy with fair to good accuracy and excellent positive predictive value.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>There was no difference in diagnostic accuracy between mRECIST, LI-RADS, and subtraction for predicting HCC response to radiation segmentectomy.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-023-10045-z","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T04:02:01Z","timestamp":1691121721000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-092X","authenticated-orcid":false,"given":"Daniel","family":"Stocker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria El","family":"Homsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gnerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Wurnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachir","family":"Taouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"10045_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557\u20132576","journal-title":"Gastroenterology"},{"key":"10045_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Allen C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3:524\u2013548","journal-title":"JAMA Oncol"},{"key":"10045_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182\u2013236","journal-title":"J Hepatol"},{"key":"10045_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358\u2013380","journal-title":"Hepatology"},{"key":"10045_CR5","unstructured":"National Comprehensive Cancer Network (2020) Hepatobiliary cancer (version 3.2020). Available via https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary_blocks.pdf. Accessed 1 June 2020"},{"key":"10045_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G et al (2022) Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 7:843\u2013850","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10045_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/radiol.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N et al (2018) Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 287:1050\u20131058","journal-title":"Radiology"},{"issue":"1358\u20131365","key":"10045_CR8","first-page":"e1351","volume":"11","author":"R Salem","year":"2013","unstructured":"Salem R, Gilbertsen M, Butt Z et al (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11(1358\u20131365):e1351","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1155\u20131163","key":"10045_CR9","first-page":"e1152","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(1155\u20131163):e1152","journal-title":"Gastroenterology"},{"issue":"497\u2013507","key":"10045_CR10","first-page":"e492","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(497\u2013507):e492","journal-title":"Gastroenterology"},{"key":"10045_CR11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jhep.2017.07.030","volume":"67","author":"S Gordic","year":"2017","unstructured":"Gordic S, Corcuera-Solano I, Stueck A et al (2017) Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology. J Hepatol 67:1213\u20131221","journal-title":"J Hepatol"},{"key":"10045_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/jmri.22038","volume":"31","author":"S Kim","year":"2010","unstructured":"Kim S, Mannelli L, Hajdu CH et al (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348\u2013355","journal-title":"J Magn Reson Imaging"},{"key":"10045_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360","journal-title":"Semin Liver Dis"},{"key":"10045_CR14","unstructured":"American Collge of Radiology (2018) CT\/MRI LI-RADS version 2018. Available via https:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/LI-RADS\/CT-MRI-LI-RADS-v2018. Accessed 03\/08\/2021"},{"key":"10045_CR15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/annonc\/mds605","volume":"24","author":"HJ Prajapati","year":"2013","unstructured":"Prajapati HJ, Spivey JR, Hanish SI et al (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24:965\u2013973","journal-title":"Ann Oncol"},{"key":"10045_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1102\/1470-7330.2013.0057","volume":"13","author":"P Singh","year":"2014","unstructured":"Singh P, Anil G (2014) Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging 13:645\u2013657","journal-title":"Cancer Imaging"},{"key":"10045_CR17","doi-asserted-by":"publisher","first-page":"e190094","DOI":"10.1148\/rycan.2020190094","volume":"2","author":"SJ Hectors","year":"2020","unstructured":"Hectors SJ, Lewis S, Kennedy P et al (2020) Assessment of hepatocellular carcinoma response to (90)Y radioembolization using dynamic contrast material-enhanced MRI and intravoxel incoherent motion diffusion-weighted imaging. Radiol Imaging Cancer 2:e190094","journal-title":"Radiol Imaging Cancer"},{"key":"10045_CR18","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1007\/s00330-020-07636-5","volume":"31","author":"P Kennedy","year":"2021","unstructured":"Kennedy P, Lewis S, Bane O et al (2021) Early effect of (90)Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. Eur Radiol 31:5791\u20135801","journal-title":"Eur Radiol"},{"key":"10045_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/03009734.2012.729104","volume":"118","author":"Y Sato","year":"2013","unstructured":"Sato Y, Watanabe H, Sone M et al (2013) Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 118:16\u201322","journal-title":"Ups J Med Sci"},{"key":"10045_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1148\/radiol.2019182135","volume":"292","author":"EL Shropshire","year":"2019","unstructured":"Shropshire EL, Chaudhry M, Miller CM et al (2019) LI-RADS treatment response algorithm: performance and diagnostic accuracy. Radiology 292:226\u2013234","journal-title":"Radiology"},{"key":"10045_CR21","doi-asserted-by":"publisher","first-page":"109351","DOI":"10.1016\/j.ejrad.2020.109351","volume":"133","author":"MJ King","year":"2020","unstructured":"King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K (2020) Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol 133:109351","journal-title":"Eur J Radiol"},{"key":"10045_CR22","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1007\/s00270-018-1991-3","volume":"41","author":"EG Klompenhouwer","year":"2018","unstructured":"Klompenhouwer EG, Dresen RC, Verslype C et al (2018) Transarterial radioembolization following chemoembolization for unresectable hepatocellular carcinoma: response based on apparent diffusion coefficient change is an independent predictor for survival. Cardiovasc Intervent Radiol 41:1716\u20131726","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10045_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00261-014-0127-8","volume":"39","author":"N Kokabi","year":"2014","unstructured":"Kokabi N, Camacho JC, Xing M et al (2014) Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging 39:969\u2013978","journal-title":"Abdom Imaging"},{"key":"10045_CR24","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jvir.2008.05.002","volume":"19","author":"TK Rhee","year":"2008","unstructured":"Rhee TK, Naik NK, Deng J et al (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19:1180\u20131186","journal-title":"J Vasc Interv Radiol"},{"key":"10045_CR25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00261-014-0295-6","volume":"40","author":"M Vouche","year":"2015","unstructured":"Vouche M, Salem R, Lewandowski RJ, Miller FH (2015) Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? Abdom Imaging 40:1471\u20131480","journal-title":"Abdom Imaging"},{"key":"10045_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/01.RVI.0000177063.92678.21","volume":"16","author":"TK Rhee","year":"2005","unstructured":"Rhee TK, Omary RA, Gates V et al (2005) The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 16:1085\u20131091","journal-title":"J Vasc Interv Radiol"},{"key":"10045_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","volume":"79","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B et al (2011) Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 79:163\u2013171","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10045_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ et al (2014) Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 60:192\u2013201","journal-title":"Hepatology"},{"key":"10045_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1037\/h0031619","volume":"76","author":"JL Fleiss","year":"1971","unstructured":"Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378\u2013382","journal-title":"Psychol Bull"},{"key":"10045_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"10045_CR31","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E et al (2021) Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY Study. Hepatology 74:2342\u20132352","journal-title":"Hepatology"},{"key":"10045_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5009\/gnl19197","volume":"14","author":"JS Lee","year":"2020","unstructured":"Lee JS, Choi HJ, Kim BK et al (2020) The Modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver 14:765\u2013774","journal-title":"Gut Liver"},{"key":"10045_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-020-02775-1","author":"WEL Ormiston","year":"2020","unstructured":"Ormiston WEL, Yarmohammadi H, Lobaugh S et al (2020) Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization. Abdom Radiol (NY). https:\/\/doi.org\/10.1007\/s00261-020-02775-1","journal-title":"Abdom Radiol (NY)"},{"key":"10045_CR34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00261-008-9454-y","volume":"34","author":"SM Ibrahim","year":"2009","unstructured":"Ibrahim SM, Nikolaidis P, Miller FH et al (2009) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34:566\u2013581","journal-title":"Abdom Imaging"},{"key":"10045_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00261-017-1281-6","volume":"43","author":"A Kielar","year":"2018","unstructured":"Kielar A, Fowler KJ, Lewis S et al (2018) Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 43:218\u2013230","journal-title":"Abdom Radiol (NY)"},{"key":"10045_CR36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.27915","volume":"62","author":"AR Seyal","year":"2015","unstructured":"Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A et al (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62:1111\u20131121","journal-title":"Hepatology"},{"key":"10045_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-08732-4","author":"N ViettiVioli","year":"2022","unstructured":"ViettiVioli N, Gnerre J, Law A et al (2022) Assessment of HCC response to yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-022-08732-4","journal-title":"Eur Radiol"},{"key":"10045_CR38","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1007\/s00330-021-07910-0","volume":"31","author":"C Kong","year":"2021","unstructured":"Kong C, Zhao Z, Chen W et al (2021) Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol 31:7500\u20137511","journal-title":"Eur Radiol"},{"key":"10045_CR39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3389\/fonc.2020.00572","volume":"10","author":"AW Moawad","year":"2020","unstructured":"Moawad AW, Fuentes D, Khalaf AM et al (2020) Feasibility of automated volumetric assessment of large hepatocellular carcinomas\u2019 responses to transarterial chemoembolization. Front Oncol 10:572","journal-title":"Front Oncol"},{"issue":"235\u2013243","key":"10045_CR40","first-page":"e233","volume":"34","author":"O Ince","year":"2023","unstructured":"Ince O, Onder H, Gencturk M, Cebeci H, Golzarian J, Young S (2023) Prediction of response of hepatocellular carcinoma to radioembolization: machine learning using preprocedural clinical factors and MR imaging radiomics. J Vasc Interv Radiol 34(235\u2013243):e233","journal-title":"J Vasc Interv Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-10045-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-023-10045-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-10045-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T12:08:48Z","timestamp":1705406928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-023-10045-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["10045"],"URL":"https:\/\/doi.org\/10.1007\/s00330-023-10045-z","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Bachir Taouli.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies:Bachir Taouli: research grants: Bayer Healthcare, Takeda; consultant: Bayer Healthcare, Guerbet. The other authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise (Moritz Wurnig).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional review board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}